Prothrombin Complex Concentrates (PCCs)

How to Cite This Chapter: Morin P-A, Ning S, Łętowska M, Rosiek A. Prothrombin Complex Concentrates (PCCs). McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. Accessed May 24, 2024.
Last Updated: October 19, 2023
Last Reviewed: October 19, 2023
Chapter Information

Prothrombin complex concentrates (PCCs) are (vitamin K–dependent) coagulation factor concentrates containining factors II, VII, IX, and X made from virally inactivated pooled plasma donations from thousands of blood donors. Storage and infusion rates vary with manufacturer recommendations. Formulations include 4-factor PCCs and 3-factor PCCs (these contain factors II, IX, and X but only small amounts of factor VII). Only 4-factor PCCs are available in Canada.


Available as lyophilized powders that must be reconstituted, PCCs are most commonly administered for the rapid reversal of warfarin-associated bleeding. PCCs are also used for the reversal of life-threatening bleeding due to anti-Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban. The maximum dose should not be >3000 IU. PCCs carry a prothrombotic risk and should only be administered in situations where the benefit of the therapy outweighs this risk.

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.